Sengenics

Enabling precision medicine

Company details

Year Aquired

2020

Location

Singapore

Revenue

11 mUSD

Sector

Life Science

Employees

40

Investment Themes

Changing Demographics

Contact

If you want to know more about Sengenics please contact Anna Ryrberg at: anna.ryrberg@summaequity.com

Sengenics produces full length, correctly folded and functional proteins to support pharma and academic research in advancing precision medicine through an increased understanding of the human proteome.

Sengenics’ KREXTM is a patented technology that enables researchers to address both the functionality and folding structure of proteins using one technology, and at high plex (# proteins) levels with high sensitivity and specificity. This enables a broad range of use cases in research and throughout the value chain for drugs, vaccines and diagnostics. Sengenics is currently focused on measurement of autoantibodies for applications in autoimmune diseases, oncology and infectious disease

 

Year Aquired

2020

Revenue

11 mUSD

Employees

40

Investment Themes

Changing Demographics

Sector

Life Science

Location

Singapore

Contact

If you want to know more about Sengenics please contact Anna Ryrberg at: anna.ryrberg@summaequity.com

Website

Video